CD274 and cancer: Based on the efficacy of pembrolizumab in PD-L1-positive cervical cancer, pembrolizumab is approved by the FDA and listed by NCCN-Compendia as a treatment option for metastatic/advanced, or recurrent cancer of the vulvar [50].